KORA SAUDE (KRSA3) Main Indicators
Basic Data - KRSA3
| Company | KORA SAUDE |
| Corporate Name | KORA SAÚDE PARTICIPAÇÕES S.A |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Holding de instituições não financeiras com fim a prestação de serviços de atenção a saúde humana. limpeza. planos de saúde. bem como outras atividades secundárias como aluguel de imóveis. |
| Share | KRSA3 |
| Quote Date | 12/02/2024 |
| Share Type | ON |
| Last Closing | R$ 6.20 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 296.33 thousand |
| Last Statement | ITR - 09/30/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | - |
| Updated 12/03/2024 | |
Relative Prices - KRSA3
| Price/Earnings | -5.24 |
| Price/SBV | 0.52 |
| Price/Net Sales | 0.21 |
| Price/CFO | 7.43 |
| Price/FCF | 166.72 |
| Price/Total Assets | 0.10 |
| Price/EBIT | 1.63 |
| Price/Working Capital | 1.31 |
| Price/NCAV | -0.14 |
| EV/EBIT | 10.57 |
| EV/EBITDA | 6.83 |
| EV/Net Sales | 1.37 |
| EV/CFO | 48.17 |
| EV/FCF | 1,080.71 |
| EV/Total Assets | 0.66 |
| Company Market Cap | R$ 479.48 M |
| Enterprise Value | R$ 3.11 B |
| Current Financial Statement Date | 09/30/2024 |
| Current Share Price | R$ 6.20 |
| Share Price Date | 12/02/2024 |
| Dividend Yield | 0.00% |
| Updated 12/03/2024 | |
Income Statement - KRSA3
| Net Revenue | R$ 2.28 B |
| Gross Result | R$ 455.27 M |
| EBIT | R$ 294.00 M |
| Depreciation and Amortization | - R$ 161.35 M |
| EBITDA | R$ 455.35 M |
| Net Profit | - R$ 91.49 M |
| Net Profit/Share | - R$ 0.12 |
| Updated 11/12/2024 | |
| Net Revenue | R$ 564.07 M |
| Gross Result | R$ 102.78 M |
| EBIT | R$ 60.53 M |
| Depreciation and Amortization | - R$ 39.41 M |
| EBITDA | R$ 99.94 M |
| Net Profit | - R$ 25.98 M |
| Profit/Share | - R$ 0.03 |
| Updated 11/12/2024 | |
Price and Volume Behavior - KRSA3
| Lowest Price 52 weeks | R$ 4.24 |
| Highest Price 52 weeks | R$ 14.00 |
| Variation 2024 | -51.56% |
| Variation 1 year | -44.64% |
| Variation 2 years(total) | -56.34% |
| Variation 2 years(yearly) | -33.89% |
| Variation 3 years(total) | -86.52% |
| Variation 3 years(yearly) | -48.70% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 216.44 thousand |
| Updated 12/03/2024 | |
Returns and Margins - KRSA3
| Return on Initial Tangible Capital | 8.64% |
| Return on Initial Invested Capital | 5.99% |
| Pre-Tax Return on Initial Tangible Capital | 13.09% |
| Pre-Tax Return on Initial Invested Capital | 9.08% |
| Return on Initial Shareholder´s Equity | -9.02% |
| Return on Initial Asset | -1.92% |
| Gross Margin | 20.00% |
| Net Margin | -4.02% |
| EBIT Margin | 12.91% |
| EBITDA Margin | 20.00% |
| Initial Asset Turnover | 0.48 |
| Financial Leverage | 5.15 |
| Liabilities/Net Worth | 4.15 |
| Net Debt/EBITDA | 5.77 |
| Updated 11/12/2024 | |
Balance Sheet - KRSA3
| Cash and Cash Equivalents | R$ 173.10 M |
| Total Assets | R$ 4.72 B |
| Short-Term Debt | R$ 452.47 M |
| Long-Term Debt | R$ 2.35 B |
| Gross Debt | R$ 2.80 B |
| Net Debt | R$ 2.63 B |
| Shareholder´s Equity | R$ 917.00 M |
| Share Book Value | R$ 1.19 |
| Common Shares | 773,348,000 |
| Preferred Shares | 0 |
| Total | 773,348,000 |
| Common Shares in Treasury | 4,307,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 4,307,000 |
| Common Shares (Except Treasury) | 769,041,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 769,041,000 |
| Updated 11/12/2024 | |
Cash Flow - KRSA3
| Operating Cash Flow | R$ 64.52 M |
| Cash Flow from Investments | - R$ 118.79 M |
| Financing Cash Flow | R$ 17.44 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 36.83 M |
| Updated 11/12/2024 | |
| Operating Cash Flow | - R$ 1.27 M |
| Cash Flow from Investments | - R$ 60.63 M |
| Financing Cash Flow | R$ 6.97 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 54.93 M |
| Updated 11/12/2024 | |
Experimental - KRSA3
| CAPEX 3 months | - R$ 18.40 M |
| Free Cash Flow 3 months | - R$ 19.67 M |
| CAPEX 12 months | - R$ 61.65 M |
| Free Cash Flow 12 months | R$ 2.88 M |
| Updated 11/12/2024 | |